References
- Hughes D, Cowell W, Koncz T et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health10, 498–509 (2007).
- Weycker D, Macarios D, Edelsberg J et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int.17, 1645–1652 (2006).
- Kothawala P, Badamgarav E, Ryu S et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin. Proc.82, 1493–1501 (2007).
- Hiligsmann M, Rabenda V, Bruyere O et al. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy96, 170–177 (2010).
- Hiligsmann M, Rabenda V, Gathon HJ et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif. Tissue Int.86, 202–210 (2010).
- Danese MD, Badamgarav E, Bauer DC. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J. Bone Min. Res.24, 1819–1826 (2009).
- Landfeldt E, Lundkvist J, Strom O. The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone48, 380–388 (2011).
- Hiligsmann M, Gathon HJ, Bruyere O et al. Cost–effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health13, 394–401 (2010).
- Lekkerkerker F, Kanis JA, Alsayed N et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos. Int.18, 1311–1317 (2007).
- Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health11, 44–47 (2008).
- Siris ES, Selby PL, Saag KG et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am. J. Med.122, S3–S13 (2009).
- Cotte FE, Mercier F, De Pouvourville G. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case–control analysis. Clin. Ther.30, 2410–2422 (2008).
- Kanis JA, Cooper C, Hiligsmann M et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos. Int.22, 2563–2573 (2011).
- Gold DT. Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses. J. Manag. Care Pharm.12, S20–S25 (2006).
- Vermeire E, Hearnshaw H, Van Royen P et al. Patient adherence to treatment: three decades of research. A comprehensive review. J. Clin. Pharm. Ther.26, 331–342 (2001).
- Rabenda V, Reginster JY. Overcoming problems with adherence to osteoporosis medication. Expert Rev. Pharmacoecon. Outcomes Res.10(6), 677–689 (2010).
- Ross S, Samuels E, Gairy K et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health14, 571–581 (2011).
- Imaz I, Zegarra P, Gonzalez-Enriquez J et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos. Int.21, 1943–1951 (2010).
- Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin. Proc.81, 1013–1022 (2006).
- Briesacher BA, Andrade SE, Yood RA et al. Consequences of poor compliance with bisphosphonates. Bone41, 882–887 (2007).
- Rabenda V, Mertens R, Fabri V et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int.19, 811–818 (2008).
- Landfeldt E, Strom O, Robbins S et al. Adherence to treatment of primary osteoporosis and its association to fractures – the Swedish adherence register analysis (SARA). Osteoporos. Int.23, 433–443 (2012).
- Gallagher AM, Rietbrock S, Olson M et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J. Bone Miner. Res.23, 1569–1575 (2008).
- Curtis JR, Larson JC, Delzell E et al. Placebo adherence, clinical outcomes, and mortality in the women’s health initiative randomized hormone therapy trials. Med. Care49, 427–435 (2011).
- Cadarette SM, Solomon DH, Katz JN et al. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos. Int.22, 943–954 (2011).
- Patrick AR, Schousboe JT, Losina E et al. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J. Clin. Endocrinol. Metab.96, 2762–2770 (2011).
- Hiligsmann M, Ethgen O, Bruyere O et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health12, 687–696 (2009).
- Cotte FE, De Pouvourville G. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv. Res.11, 151 (2011).
- Kanis JA, Adams J, Borgstrom F et al. The cost–effectiveness of alendronate in the management of osteoporosis. Bone42, 4–15 (2008).
- Ström O, Borgström F, Kanis JA et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos. Int.20, 23–34 (2009).
- Jonsson B, Strom O, Eisman JA et al. Cost–effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos. Int.22, 967–982 (2011).
- Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics29, 895–911 (2011).
- Bone HG, Hosking D, Devogelaer JP et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med.350, 1189–1199 (2004).
- Bagger YZ, Tanko LB, Alexandersen P et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone33, 301–307 (2003).
- Lo JC, Pressman AR, Omar MA et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos. Int.17, 922–928 (2006).
- Brookhart MA, Avorn J, Katz JN et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am. J. Med.120, 251–256 (2007).
- Schousboe JT, Taylor BC, Fink HA et al. Cost–effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA298, 629–637 (2007).
- Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics26, 513–536 (2008).
- Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone38, 922–928 (2006).
- Kendler DL, Bessette L, Hill CD et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos. Int.21, 837–846 (2010).
- Cotte FE, Cortet B, Lafuma A et al. A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine75, 201–208 (2008).
- Cotte FE, Fautrel B, De Pouvourville G. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med. Decis. Making29, 125–139 (2009).
- Earnshaw SR, Graham CN, Ettinger B et al. Cost–effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr. Med. Res. Opin.23, 2517–2529 (2007).
- Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM102, 35–42 (2009).
- Hiligsmann M, McGowan B, Bennett K et al. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health (2012) (In press).
- Vrijens B, Vincze G, Kristanto P et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ336, 1114–1117 (2008).
- Breuil V, Cortet B, Cotte FE et al. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos. Int.23, 445–455 (2012).
- Papaioannou A, Kennedy CC, Dolovich L et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging24, 37–55 (2007).
- Hughes DA, Bagust A, Haycox A et al. The impact of non-compliance on the cost–effectiveness of pharmaceuticals: a review of the literature. Health Econ.10, 601–615 (2001).
- Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy59, 65–94 (2002).
- Rosen AB, Spaulding AB, Greenberg D et al. Patient adherence: a blind spot in cost–effectiveness analyses? Am. J. Manag. Care15, 626–632 (2009).
- Cherry SB, Benner JS, Hussein MA et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health12, 489–497 (2009).
- Breitscheidel L, Stamenitis S, Dippel FW et al. Economic impact of compliance to treatment with antidiabetes medication in Type 2 diabetes mellitus: a review paper. J. Med. Econ.13, 8–15 (2010).
- Salas M, Hughes D, Zuluaga A et al. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health12, 915–922 (2009).
- Cleemput I, Kesteloot K, Vanrenterghem Y et al. The economic implications of non-adherence after renal transplantation. Pharmacoeconomics22, 1217–1234 (2004).